Fig 1: Immunohistochemical features of CD20+ B lymphocyte co-localization with different immune exhaustion molecules in CRC. (A) Double immunohistochemical staining of CRC tissue sections from short-term survivors shows a frequent co-localization of BTLA (brown) with CD20 (red). Magnification: X400. Scale bars: 20 µm. (B) Double immunohistochemical staining of CRC tissue sections from short-term survivors shows a frequent co-localization of TRAF1 (brown) with CD20 (red). Magnification: X400. Scale bars: 20 µm. (C) Double immunohistochemical staining of CRC tissue sections from short-term survivors shows a frequent co-localization of SIGLEC6 (red) with CD20 (brown). Magnification: X400. Scale bars: 20 µm.
Fig 2: Survival curves and immunopathological features of BTLA, SIGLEC6, and CD20/FCRL4 expression in CRC patients from the PanCancer collection and from the validation cohort. (A) Kaplan-Meier curves representing, for each time point, the fraction of surviving CRC patients classified, based on mRNA expression levels in tumor samples, as BTLA mRNAhigh (n. 15) and BTLA mRNAlow (n. 573). (B) Kaplan-Meier curves representing, for each time point, the fraction of surviving CRC patients classified, based on mRNA expression levels in tumor samples, as FCRL4 mRNAhigh (n. 11) and FCRL4 mRNAlow (n. 351). (C) Kaplan-Meier curves representing, for each time point, the fraction of surviving CRC patients classified, based on mRNA expression levels in tumor samples, as SIGLEC6 mRNAhigh (n. 18) and SIGLEC6 mRNAlow (n. 570). (D) Kaplan-Meier curves representing, for each time point, the fraction of surviving CRC patients classified, based on mRNA expression levels in tumor samples, as CD20 mRNAhigh + FCRL4 mRNAhigh (n. 8) andCD20 mRNAlow + FCRL4 mRNAlow (n. 354). (E) Expression of BTLA in CRC tissue sections obtained from patients with long- and short-term survival. Magnification: X400. Scale bars: 20 µm. (F) Expression of SIGLEC6 in CRC tissue sections obtained from patients with long- and short-term survival. Magnification: X400. Scale bars: 20 µm. (G) Expression of FCRL4 in CRC tissue sections obtained from patients with long- and short-term survival. Magnification: X200. Scale bars: 30 µm. (H) Co-expression of CD20 (red) and FCRL4 (brown) in CRC tissue sections obtained from patients with long- and short-term survival. Magnification: X400. Scale bars: 20 µm.
Supplier Page from Abcam for Anti-SIGLEC6 antibody